Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: A biodistribution and survival study

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 1, 2008, Pages 32-37

  Vali, Mustafa ^a   Vossen, Josephina A ^a   Buijs, Manon ^a   Engles, James M ^a   Liapi, Eleni ^a   Ventura, Veronica Prieto ^a   Khwaja, Afsheen ^a   Acha Ngwodo, Obele ^a   Shanmugasundaram, Ganapathy ^a   Syed, Labiq ^a   Wahl, Richard L ^a   Geschwind, Jean Francois H ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b Division of Vascular and Interventional Radiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOPYRUVIC ACID; CARBON 14; FLUORODEOXYGLUCOSE F 18; GLUCOSE; PYRUVIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; DRUG UPTAKE; GLUCOSE METABOLISM; HISTOLOGY; ISOTOPE LABELING; LIVER TUMOR; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RABBIT; SURVIVAL RATE;

ANIMALS; CARBON RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS, EXPERIMENTAL; PYRUVATES; RABBITS; TISSUE DISTRIBUTION;

EID: 52649158301     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.141093     Document Type: Article

References (20)

1. Bomanji JB, Costa DC, and Ell PJ (2001) Clinical role of positron emission tomography in oncology. Lancet Oncol 2:157-164.
2. Bruix J and Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208-1236.
3. Del Pozo AC and López P (2007) Management of hepatocellular carcinoma. Clin Liver Dis 11:305-321.
4. Egawa H, Maki A, Mori K, Yamamoto Y, Mitsuhashi S, Bannai K, Asano K, and Ozawa K (1990) Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats. J Surg Oncol 44:109-114.
5. Fattovich G, Stroffolini T, Zagni I, and Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127:S35-S50.
6. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, and Wolf AP (1978) Metabolic trapping as a principle of oradiopharmaceutical design: some factors responsible for the biodistribution of [18F]2-deoxy-2-fluoro-D-glucose. J Nucl Med 19:1154-1161.
7. Gatenby RA and Gillies RJ (2007) Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol 39:1358-1366.
8. Georges E, Breitburd F, Jibard N, and Orth G (1985) Two Shope papillomavirus-associated VX2 carcinoma cell lines with different levels of keratinocyte differentiation and transplantability. J Virol 55:246-250.
9. Georgiades CS, Ramsey DE, Solomon S, and Geschwind JF (2001) New nonsurgical therapies in the treatment of hepatocellular carcinoma. Tech Vasc Interv Radiol 4:193-199.
10. Geschwind JF, Ko YH, Torbenson MS, Magee C, and Pedersen PL (2002) Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62:3909-3913.
11. Ko YH, Pedersen PL, and Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173:83-91.
12. Konno T (1990) Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer 66:1897-1903.
13. Kumar R, Nadig MR, and Chauhan A (2005) Positron emission tomography: clinical applications in oncology. Part 1. Expert Rev Anticancer Ther 5:1079-1094.
14. Nishizaki T, Matsumata T, Kanematsu T, Yasunaga C, and Sugimachi K (1990) Surgical manipulation of VX2 carcinoma in the rabbit liver evokes enhancement of metastasis. J Surg Res 49:92-97.
15. Park HS, Chung JW, Jae HJ, Kim YI, Son KR, Lee MJ, Park JH, Kang WJ, Yoon JH, Chung H, et al. (2007) FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model. Korean J Radiol 8:216-224.
16. Rous P, Kidd JG, and Smith WE (1952) Experiments on the cause of the rabbit carcinomas derived from virus-induced papillomas. II. Loss by the Vx2 carcinoma of the power to immunize hosts against the papilloma virus. J Exp Med 96:159-174.
17. Shaw RJ (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18:598-608.
18. Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson MS, Georgiades C, and Geschwind JF (2007) Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol 18:95-101.
19. Wagner HN Jr (1993) Oncology: a new engine for PET/SPECT. Highlights of the Society of Nuclear Medicine annual meeting. J Nucl Med 34:13N-16N, 19N, 22N-29N.
20. Warburg O (1956) On the origin of cancer cells. Science 123:309-314.